Gene Inger’s Trading Notebook: Why retailers like Nordstrom, Walmart and Home Depot are flat a...
Update PepsiCo (PEP)
10/02/2009 3:09 pm EST
Is the stock market entering a more defensive phase with "safe" sectors such as consumer goods set to outperform for a while?
Looks like it to me given the recent data on which sectors have turned hot and which are cooling off. (See my October 1 post for some of that data.)
And I got more confirmation from the big pop that shares of "safe" PepsiCo (NYSE: PEP) got this morning after a an upgrade from Deutsche Bank. The upgrade wasn't huge—the bank raised its 12-month target price to $70 from $66—but the stock is up $2.47 a share, or 4.2%, as of 12:40 pm (ET) on what isn't particularly striking news. To me, that shows that there are a lot of investors out there who, right now, want to lower their risk, but stay in stocks.
I'm going to raise my target price on this evidence that safe consumer stocks are back in favor.
In raising its target price, Deutsche Bank cited its reading of a recent filing by PepsiCo with the Securities & Exchange Commission (SEC) that implied lower interest expenses and lower depreciation than they had expected as a result of PepsiCo's acquisition of bottlers PepsiAmerica and Pepsi Bottling Group. As a result, the bank raised its 2010 earnings forecast to $4.20, an increase of 4 cents. (See, I told you this wasn't exactly earth-shaking news!)
More importantly, Deutsche Bank also said that they think there could well be more increases to earnings estimates ahead from a potential tailwind from a weak US dollar and lower costs for key raw materials. With investors getting edgy about prospects for earnings growth in the fourth quarter and in 2010, that's a compelling story.
As of October 2, 2009, I'm raising my target price for PepsiCo to $68 a share by June 2010 from my previous target of $62 by March 2010.
Full disclosure: I don’t own shares of any company mentioned in this post in my personal portfolio.
Related Articles on STOCKS
When we recommended pharmaceutical giant AbbVie (ABBV) this past June, it had recently raised its qu...
Eli Lilly (LLY) manufactures drugs to treat pain, diabetes, and cancer. It also produces animal heal...
Verisk Analytics (VRSK) has broken out of a nine-week, classic double bottom base. The move carries ...